Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Statin shows promise for COPD inflammation in small trial

NCT ID NCT07549932

Disease control Sponsor: Mohamed Salah El-Sayed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether adding a daily statin (atorvastatin 20 mg) to standard treatment for six months could reduce airway inflammation and improve lung function in 80 people with severe COPD. Researchers measured blood markers of inflammation and breathing tests. The goal was to see if this cheap, widely available drug could offer extra benefits for COPD management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atorvastatin (statin)
What this could lead to
If statins prove helpful, they could become a low-cost add-on treatment to reduce inflammation and slow COPD progression.
What could go wrong
This is a small, completed study with no phase designation, so results may not be conclusive. Statins also carry risks like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed Chronic Obstructive Pulmonary Disease per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 2025 (post-bronchodilator forced expiratory volume₁/forced vital capacity \< 0.70), meets the definition of grade E Chronic Obstructive Pulmonary Disease by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 2025 criteria. * Age ≥ 40 years Exclusion Criteria: * Chronic lung diseases other than COPD as bronchial asthma, interstitial lung disease * Acute or chronic Inhalational lung injury. * Established indication for statin therapy (atherosclerotic cardiovascular disease, familial hyperlipidemia). * Chronic debilitating diseases as diabetes mellitus, chronic liver disease, chronic kidney disease, and hematological disorders. * Pregnancy/lactation. * Known hypersensitivity to statins. * Unable or refuse to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Airway disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Airway disease Chronic obstructive pulmonary disease STATIN

Contacts and locations

Locations

  • utpatient clinic and Inpatient quarters of the Thoracic Medicine Department of Mansoura University Hospitals

    Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.